

Paris, 29 April 2024

Dear Sir/Madam,

Thank you for including in your portfolio one or more shares of the **Amundi STOXX Europe 600 Healthcare** sub-fund.

**Your sub-fund will absorb on 5 June 2024 the Amundi ETF MSCI Europe Healthcare UCITS ETF**, a French Fonds Commun de Placement (“FCP”). In concrete terms, this means that the Amundi STOXX Europe 600 Healthcare you hold will receive assets from the Amundi ETF MSCI Europe Healthcare UCITS ETF, without any change on the characteristics of your sub-fund nor the number of shares you currently hold.

Please note that this absorption does not require any action on your part. In addition, the investment objectives and fees remain unchanged.

The details of this operation are explained in the attached document entitled “Notice to Shareholders: Amundi STOXX Europe 600 Healthcare”. This notice, which has been approved by the CSSF, provides all the information required for these operations by the regulations in force. This full and accurate document allows you to familiarize yourself with the potential implications of this operation for your investment. We therefore recommend that you read it carefully.

Your usual financial adviser will be glad to provide any additional information you may require.

**For further information, please contact client services on +(352) 4212030 or via e-mail at [info\\_de@amundi.com](mailto:info_de@amundi.com).**

Yours faithfully,

**AMUNDI ASSET MANAGEMENT**

Benoit Sorel

Director – ETF, Indexing & Smart Beta

**Multi Units Luxembourg**  
*Société d'investissement à capital variable*  
Registered office: 9 rue de Bitbourg, L-1273 Luxembourg, Grand Duchy of Luxembourg  
R.C.S. Luxembourg B 115 129

Luxembourg, 29 April 2024

## **NOTICE TO SHAREHOLDERS: Amundi STOXX Europe 600 Healthcare**

**Merger into Amundi STOXX Europe 600 Healthcare (the “Receiving Sub-Fund”)**

What this notice includes:

- **Explanatory letter** of the Merger
  - **Appendix I:** Timeline for the Merger
-

Dear Shareholder,

As part of the ongoing review of the product range competitiveness and client interest assessment, it has been decided to proceed with the merger of:

(1) **Amundi ETF MSCI Europe Healthcare UCITS ETF**, a French *Fonds Commun de Placement* (“FCP”), (the “**Absorbed Sub-Fund**”);

into

(2) **Amundi STOXX Europe 600 Healthcare**, a sub-fund of Multi Units Luxembourg in which you own shares (the “**Receiving Sub-Fund**”);

(the “**Merger**”).

**You are receiving this notice as a shareholder of the Receiving Sub-Fund. As such, your sub-fund is receiving a different sub-fund by way of the Merger. As further described in this notice, please note that the characteristics of the Receiving Sub-Fund will remain the same after the implementation of the Merger.**

This notice is issued and sent to you to provide appropriate and accurate information on the Merger to enable you to make an informed judgment of the impact of the Merger on your investment.

Please note that the Merger will be processed automatically on the relevant dates indicated in Appendix I (the “**Merger Effective Date**”). It is not subject to your prior approval, vote or consent.

If you do not wish to participate to the Merger, however, you can request the redemption or the conversion of your shares in the Receiving Sub-Fund in accordance with Paragraph B of this notice.

Please take a moment to review the important information below. Should you have any question with respect to this notice or the Merger, please contact your financial advisor. Alternatively, you may also contact the management company by mail sent at:

Amundi Asset Management S.A.S.  
91-93, boulevard Pasteur  
75015 Paris  
France

Yours faithfully,

The Board

---

## A. Impact of the Merger on Shareholders of the Receiving Sub-Fund

On the Merger Effective Date, all the assets and liabilities of the relevant Absorbed Sub-Fund will be transferred to the Receiving Sub-Fund. Shareholders in the Receiving Sub-Fund should benefit from the increased investment capacity in the Receiving Sub-Fund and the economies of scale this Merger should allow to achieve.

Like the Receiving Sub-Fund, the Absorbed Sub-Fund is an undertakings for collective investment in transferable securities (UCITS) subject to investment rules substantially similar to those of the Receiving Sub-Fund. The Absorbed Sub-Fund is a French *Fonds Commun de Placement* and the Receiving Sub-Fund a sub-fund of a Luxembourg SICAV. Where required, the portfolio of the Absorbed Sub-Fund will be adjusted prior to the Merger so that no rebalancing of the Receiving Sub-Fund's portfolio will be required before or after the Merger.

On implementation of the Merger, shareholders in the Receiving Sub-Fund will continue to hold the same shares in the Receiving Sub-Fund as before and there will be no change in the rights attaching to such shares. The characteristics of the Receiving Sub-Fund will remain the same after the Merger Effective Date and the implementation of the Merger will not affect the fee structure of the Receiving Sub-Fund.

**Shareholders are however advised to contact a tax adviser and to clarify individually any possible tax consequences resulting from the Merger.**

## B. Terms and Conditions of the Merger

Shareholders who do not agree with the terms and conditions of the Merger have the right to redeem or convert their shares at any time free of charges (excluding redemption fees charged by the Receiving Sub-Fund to cover divestment fees and except for the fees acquired by the Receiving Sub-Fund to prevent dilution of shareholders investment) from the date of this notice until the **"Last Day to Request Redemption or Conversion Free of Charge for Primary Market Investors"** as set out in Appendix I.

**Nevertheless, placing an order on the secondary market will trigger costs over which the management company of the Receiving Sub-Fund has no influence. Please note that shares that are purchased on the secondary market cannot generally be sold back directly to the Receiving Sub-Fund. As a result, investors operating on the secondary market may incur intermediary and/or brokerage and/or transaction fees on their transactions, over which the management company of the Receiving Sub-Fund has no influence. These investors will also trade at a price that reflects the existence of a bid-ask spread. Such investors are invited to contact their usual broker for further information on the brokerage fees that may apply to them and the bid-ask spreads they are likely to incur.**

Such a redemption would be subject to the ordinary rules of taxation applicable to capital gains on the sale of transferable securities.

Any subscription, conversion or redemption request on the primary market received by the Receiving UCITS, the Receiving UCITS' management company, the Distribution, Paying or Information Agent by the applicable cut-off time on the Merger Effective Date will be processed on the following day that is a Business Day.

The Merger will be binding on all the shareholders of the Receiving Sub-Fund who have not requested the redemption or the conversion of their shares in the Receiving Sub-Fund in accordance with this Paragraph B.

The cost of the Merger will be fully supported by the management company of the Receiving Sub-Fund.

---

## C. Documentation

The following documents are at the disposal of shareholders for inspection and for copies free of charge during normal business hours at the registered office of the Receiving UCITS:

- the common terms of Merger;
  - the latest prospectus and KID of the Receiving Sub-Fund;
  - copy of the merger report prepared by the auditor;
  - copy of the statement related to the Merger issued by the depositary of each of the Absorbed Sub-Fund and the Receiving Sub-Fund.
-

**APPENDIX I**  
**Timeline for the Merger**

| <b>Event</b>  | <b>Date</b>   |
|---|---------------|
| <b>Beginning of Redemption Period</b>   | 29 April 2024 |
| <b>Last Day to Request Redemption free of charge for primary market investors</b> | 4 June 2024   |
| <b>Merger Effective Date</b>  | 5 June 2024*  |

\* or such later time and date as may be determined by the board of directors of the Absorbed Sub-Fund and the Receiving Sub-Fund and notified in writing to shareholders. In the event that the boards of directors approve a later Merger Effective Date, they may also make such consequential adjustments to the other elements in this timetable as they consider appropriate.